Virtually, PD-L1 on the melanoma tumor cells was blocked by CD64-NVs-aPD-L1 formulation in vivo, which promoted the anti-tumor effect of CD8+ T cells by enhancing activation and proliferation. This evidence concerns the gene CD8A and melanoma.